Literature DB >> 16399080

Dose-dependent interaction of Tbx1 and Crkl and locally aberrant RA signaling in a model of del22q11 syndrome.

Deborah L Guris1, Gregg Duester, Virginia E Papaioannou, Akira Imamoto.   

Abstract

22q11 deletion (del22q11) syndrome is characterized genetically by heterozygous deletions within chromosome 22q11 and clinically by a constellation of congenital malformations of the aortic arch, heart, thymus, and parathyroid glands described as DiGeorge syndrome (DGS). Here, we report that compound heterozygosity of mouse homologs of two 22q11 genes, CRKL and TBX1, results in a striking increase in the penetrance and expressivity of a DGS-like phenotype compared to heterozygosity at either locus. Furthermore, we show that these two genes have critical dose-dependent functions in pharyngeal segmentation, patterning of the pharyngeal apparatus along the anteroposterior axis, and local regulation of retinoic acid (RA) metabolism and signaling. We can partially rescue one salient feature of DGS in Crkl+/-;Tbx1+/- embryos by genetically reducing the amount of RA produced in the embryo. Thus, we suggest that del22q11 is a contiguous gene syndrome involving dose-sensitive interaction of CRKL and TBX1 and locally aberrant RA signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399080     DOI: 10.1016/j.devcel.2005.12.002

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  90 in total

1.  Canonical Wnt signaling modulates Tbx1, Eya1, and Six1 expression, restricting neurogenesis in the otic vesicle.

Authors:  Laina Freyer; Bernice E Morrow
Journal:  Dev Dyn       Date:  2010-06       Impact factor: 3.780

Review 2.  Understanding the role of Tbx1 as a candidate gene for 22q11.2 deletion syndrome.

Authors:  Shan Gao; Xiao Li; Brad A Amendt
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

3.  Identification of putative retinoic acid target genes downstream of mesenchymal Tbx1 during inner ear development.

Authors:  Dennis C Monks; Bernice E Morrow
Journal:  Dev Dyn       Date:  2012-02-01       Impact factor: 3.780

Review 4.  The neural crest in cardiac congenital anomalies.

Authors:  Anna Keyte; Mary Redmond Hutson
Journal:  Differentiation       Date:  2012-05-15       Impact factor: 3.880

5.  Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes.

Authors:  Anne M Moon; Deborah L Guris; Ji-heui Seo; Leiming Li; Jennetta Hammond; Amy Talbot; Akira Imamoto
Journal:  Dev Cell       Date:  2006-01       Impact factor: 12.270

Review 6.  Model systems for the study of heart development and disease. Cardiac neural crest and conotruncal malformations.

Authors:  Mary R Hutson; Margaret L Kirby
Journal:  Semin Cell Dev Biol       Date:  2006-12-19       Impact factor: 7.727

7.  Mesodermal expression of Tbx1 is necessary and sufficient for pharyngeal arch and cardiac outflow tract development.

Authors:  Zhen Zhang; Tuong Huynh; Antonio Baldini
Journal:  Development       Date:  2006-08-16       Impact factor: 6.868

8.  Molecular characterization of deletion breakpoints in adults with 22q11 deletion syndrome.

Authors:  Rosanna Weksberg; Andrea C Stachon; Jeremy A Squire; Laura Moldovan; Jane Bayani; Stephen Meyn; Eva Chow; Anne S Bassett
Journal:  Hum Genet       Date:  2006-10-07       Impact factor: 4.132

9.  Transcription factor TBX1 overexpression induces downregulation of proteins involved in retinoic acid metabolism: a comparative proteomic analysis.

Authors:  Marianna Caterino; Margherita Ruoppolo; Gabriella Fulcoli; Tuong Huynth; Stefania Orrù; Antonio Baldini; Francesco Salvatore
Journal:  J Proteome Res       Date:  2009-03       Impact factor: 4.466

10.  Signature MicroRNA expression patterns identified in humans with 22q11.2 deletion/DiGeorge syndrome.

Authors:  M Teresa de la Morena; Jennifer L Eitson; Igor M Dozmorov; Serkan Belkaya; Ashley R Hoover; Esperanza Anguiano; M Virginia Pascual; Nicolai S C van Oers
Journal:  Clin Immunol       Date:  2013-01-30       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.